Company intelligence / Profile preview

Locus Cell

New Taipei, New Taipei, Taiwan

Ownership: Private
Employees: ~53
Development stage: Other

Overview

Locus Cell provides GMP-certified CDMO services focused on cell therapies, including tissue engineering, CAR-T, iPSC, and MSC products, supporting both clinical trials and commercial manufacturing. Its facility has secured international Phase III manufacturing contracts for advanced therapies such as Elate Ocular®, a dry eye disease therapy in clinical development.

Modalities: Cell therapyInduced pluripotent stem cell derived therapyCAR-T cell therapyMesenchymal stem cell therapyTissue engineering
Industry: Contract Manufacturing Organization

Partnerships

Cambium Bio

Beyond the preview

Go deeper on Locus Cell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Locus Cell.

Explore the full profile